Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events

被引：0
作者：
Sara Lee
Christopher P. Cannon
机构：
[1] Temple University School of Pharmacy,Cardiovascular Division, Harvard Medical School
[2] Brigham and Women’s Hospital,undefined
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Statin therapy; PCSK9 inhibitors; Cholesterol; Cardiovascular risk;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 27 条
  • [11] Watts GF(2011)Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2255-212
  • [12] Cohen JC(2014)Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 203-42
  • [13] Boerwinkle E(2016)CETP inhibition: past failures and future hopes Clin Med Insights Cardiol 10 37-1227
  • [14] Mosley THJ(2017)Effects of anacetrapib in patients with atherosclerotic vascular disease N Engl J Med 377 1217-986
  • [15] Hobbs HH(2016)Lp(a) and cardiovascular risk: investigating the hidden side of the moon Nutr Metab Cardiovasc Dis 26 980-undefined
  • [16] Keating GM(undefined)undefined undefined undefined undefined-undefined
  • [17] Croom KF(undefined)undefined undefined undefined undefined-undefined
  • [18] Farnier M(undefined)undefined undefined undefined undefined-undefined
  • [19] McKenney J(undefined)undefined undefined undefined undefined-undefined
  • [20] Kosmas CE(undefined)undefined undefined undefined undefined-undefined
123